Boca Raton, FL, July 06, 2020 (GLOBE NEWSWIRE) -- Connectyx Technologies Holdings Group, Inc. (OTC: CTYX) (“Connectyx” or the “Company”), a development-stage biomedical company focusing on novel treatments for rare diseases today announced it is in licensing discussions for a novel monoclonal antibody (mAB) to treat brain cancer. The Company plans to grow its product pipeline through an active program of acquisition, in-licensing and sub-licensing of new technologies.
Connectyx has evaluated hundreds of available pharmaceutical assets, and the management, along with the Scientific Advisory Board, have identified a novel mAB available for license to treat pediatric glioblastoma. Pediatric glioblastoma (also sometimes called grade IV astrocytoma) is a malignant brain tumor that is aggressive and without a defined standard therapy. The current prognosis for children with glioblastoma is very poor, with estimates placing the overall median survival rate at 15 months.
Connectyx is currently involved in licensing discussions with the owner of the intellectual property for an exclusive worldwide license. This product leverages the Company’s Scientific Advisory Board, that has deep experience in clinical development and manufacturing in this field.
“Our potential first target indication addresses an area of urgent underserved medical need, services a population suffering from a rare disease, and offers a substantial market opportunity. These are all elements of the company’s mission of aspiring to grow into an organization that fulfills the unmet needs of patients with rare diseases,” Paul M. Michaels, newly-appointed Chief Executive Officer and Director said.
“The Scientific Advisory Board: Dr. Ronald Bordens, I. Richard Garr, Esq. and Dr. Michael Grace, along with Dr. Barry Ginsberg, Chief Strategy Officer, have been instrumental in identifying and developing this opportunity. I am thankful for the efforts of this high-quality team,” Michaels concluded.
About Connectyx Technologies Holdings Group, Inc. http://connectyx.com/
Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is transforming through the acquisition, in-licensing and sub-licensing of new technologies. At Connectyx, we envision a world where all patients have a therapeutic option.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. CTYX has great potential but is not yet generating revenues. Although forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subjected to known, unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements, including but not limited to our ability to maintain our website and associated computer systems, our ability to generate sufficient market acceptance for our products and services, our ability to generate sufficient operating cash flow, and general economic conditions. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with OTC Markets from time to time which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Connectyx Technologies Holdings Group, Inc
Get the Latest CTYX - Connectyx Technologies Holdings Group, Inc. News & Updates!